Fingolimod (FTY-720)

製品コードS5950 バッチS595004

印刷

化学情報

Synonyms

FTY-720A

Storage
(From the date of receipt)

3 years -20°C powder

化学式

C₁₉H₃₃NO₂

分子量

307.47

CAS No.

162359-55-9

Solubility (25°C)*

体外

DMSO

61 mg/mL (198.39 mM)

Ethanol

31 mg/mL (100.82 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Fingolimod (FTY-720) is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis.
in vitro	It reversibly redistributes T and B cells from the circulation to secondary lymphoid organs like peripheral and mesenteric lymph nodes and Peyer's patches, thereby causing a state of peripheral lymphopenia^[1].
in vivo	Absorption is food-independent and slow (maximal plasma concentration after 12-16 h), but extensive, and its bioavailability is high (93%). It reaches steady state concentrations after 1-2 months during daily intake.It has a large volume of distribution of approx. 20L/kg and shows slow blood clearance (6.3±2.3 L/h), resulting in a half-life of 6-9 days^[1].

製品説明

Fingolimod (FTY-720) is a sphingosine 1-phosphate receptor modulator used for the treatment of relapsing-remitting multiple sclerosis.

in vitro

It reversibly redistributes T and B cells from the circulation to secondary lymphoid organs like peripheral and mesenteric lymph nodes and Peyer's patches, thereby causing a state of peripheral lymphopenia^[1].

in vivo

Absorption is food-independent and slow (maximal plasma concentration after 12-16 h), but extensive, and its bioavailability is high (93%). It reaches steady state concentrations after 1-2 months during daily intake.It has a large volume of distribution of approx. 20L/kg and shows slow blood clearance (6.3±2.3 L/h), resulting in a half-life of 6-9 days^[1].

プロトコル(参考用のみ)

細胞アッセイ	細胞株	NSCLC cells
	濃度	10 μM
	反応時間	72 h
	実験の流れ	Cells were treated with various concentrations of drug for 72 h.
動物実験	動物モデル	C57/B6 mice
	投薬量	1 mg/kg
	投与方法	o.g.

参考

https://pubmed.ncbi.nlm.nih.gov/29127024/
https://pubmed.ncbi.nlm.nih.gov/21740973/
https://pubmed.ncbi.nlm.nih.gov/35831279/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial [ Nat Commun, 2024, 15(1):6970]	PubMed: 39138212
Clinical and radiological implications of subpotent generic fingolimod in multiple sclerosis: a case series [ Ther Adv Neurol Diso, 2024, 17:17562864241300047]	PubMed: 39574836
A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells [ Oncol Res, 2023, 31(6):867-875]	PubMed: 37744269
Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity [ J Clin Invest, 2022, 132(3)e153604]	PubMed: 35104810
Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity [ J Clin Invest, 2022, 132(3)e153604]	PubMed: 35104810
Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy [ J Immunother Cancer, 2022, 10(5)e003960]	PubMed: 35623658
The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC [ Clin Transl Med, 2022, 12(2):e695]	PubMed: 35184376
The sphingosine kinase inhibitor SKI-V suppresses cervical cancer cell growth [ Int J Biol Sci, 2022, 18(7):2994-3005]	PubMed: 35541904
Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth [ Cell Death Dis, 2022, 13(7):602]	PubMed: 35831279
Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis [ Pharmaceutics, 2022, 14(7)1420]	PubMed: 35890315

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。